Dermatology experts Susan Taylor, Iltefat Hamzavi, and Seemal Desai discuss vitiligo's clinical and economic burden, its autoimmune pathogenesis, diagnostic workup, disease activity assessment, first- and second-line treatment, and emerging systemic therapies, with a direct appeal to payers to recognize and cover the disease appropriately.
This video was supported independently by Pfizer.
Panelists discuss how persistent undertreatment, shifting guidelines, therapy access barriers, and economic burden all contribute to poor LDL-C control, underscoring the need for renewed focus on outcomes-driven strategies to reduce cardiovascular risk.
Ryan Haumschild, PharmD, MBA, MS; Sandeep Sahay, MD, FCCP; Murali Chakinala, MD, FCCP, and Marius M. Hoeper, MD, discuss how pulmonary arterial hypertension management has evolved with new therapeutic pathways like sotatercept offering reverse remodeling capabilities, requiring individualized treatment approaches that balance disease severity, patient preferences, and economic considerations while emphasizing early diagnosis and aggressive upfront combination therapy to achieve disease remission and reduce long-term healthcare costs.
This program explores how Continuous Glucose Monitoring (CGM) technology addresses therapeutic inertia, enhances glycemic control, and its role in quality metrics. Panelists examine the evidence to support expanding CGM access to broader diabetes populations in alignment with the 2025 ADA Standards of Care. The program will focus on overcoming barriers to CGM adoption and improving access in diverse patient populations, addressing racial and ethnic disparities. Additionally, this program will evaluate CGM’s impact on reducing healthcare resource utilization and cost management strategies to improve patient outcomes.
This program was supported through an independent medical education grant from Dexcom Medical Affairs.
A comprehensive panel discussion by cardiometabolic risk management experts addresses the impact, prevention, management, and treatment of cardiometabolic conditions, exploring adherence challenges, care coordination strategies, recent studies, and innovative approaches to improve patient outcomes.
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Dr. Derek Van Amerongen, Dr. Alpesh Amin, Dr. Arun Jesudian, Jordan Mayberry, and Dr. Apurva Modi discuss evaluating the clinical and economic burden of Hepatic Encephalopathy (HE), reviewing current management strategies, and exploring best practices for coordination of care and optimization for transitions of care.
This series was supported by Salix Pharmaceuticals.
Nihar Desai, MD, MPH; Natalie Evans, MD, MS, FAHA; Seth S. Martin, MD, MHS, FACC, FASPC, FAHA; and Pam R. Taub, MD, FACC, FASPC, discuss disparities in cardiovascular disease management and their vision for more equitable care.
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD; discuss the current landscape and treatment of Dry Eye Disease.
Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a discussion regarding the current and prospective treatment landscape for CKD.
A panel of experts provide an overview of the clinical, economic, and humanistic burden of inflammatory conditions in the US, discuss the role of biologics and biosimilars in disease management and practical considerations for drug selection, define interchangeable biosimilars and discuss the potential value of these agents to patients, payers, and providers in the treatment of inflammatory diseases.
This activity is supported by an educational grant from Boehringer Ingelheim.
A panel of experts discuss the current state of health equity in women's health, including representation of racial/ethnic groups in clinical trials, access to care, and disparities in care for specific disease states.
An expert panel discusses associated burdens, treatment considerations, and disparities in care management of patients with psoriasis.
The information discussed in this series is a consensus from the Diabetes Cardiorenal & Metabolism Institute (DCMi) think Tank, a workshop consisting of 17 medical experts to create treatment consensuses based on data and expert opinion, for patients with complex multimorbid diseases plateauing or worsening in outcomes despite the emergence of numerous therapeutic options available. The DCMi will soon have a published consensus paper on early intervention and intensive management of the patient with diabetes and cardio-renal-metabolic diseases which compliments the DCRM multi-specialty practice accommodations.
Experts from US Oncology, Tennessee Oncology, AON, and COA discuss the details of implementing the Enhancing Oncology Model.
Neil Minkoff, MD; Maria Lopes, MD, MS; Nancy Ross, PharmD, BCACP, MSCS, CSP; Thomas Leist, MD; and Darin Okuda, MD explore opportunities for improving long-term patient outcomes in MS through earlier use of high efficacy therapies, including those of clinical and payer consideration.
Various stakeholders who play a role in the management of chronic obstructive pulmonary disease (COPD) explore various topics pertaining to the current treatment of COPD and discuss the adoption of measuring peak inspiratory flow rates into clinical practice.
